Zapata Bonilla SA, Fried M, Singer S, Hentschel L, Richter S, Hohenberger P, Kasper B, Andreou D, Pink D, Arndt K, Bornhäuser M, Schmitt J, Schuler MK, Eichler M. Working situation and burden of work limitations in sarcoma patients: results from the multi-center prospective PROSa study. J Cancer Res Clin Oncol. 2023 Jan 10. doi: 10.1007/s00432-022-04556-3. Epub ahead of print. PMID: 36624191

Krämer I, Rosentreter J, Fried M, Kühn M. Significant interaction between high-dose methotrexate and high-dose piperacillin-tazobactam causing reversible neurotoxicity and renal failure in an osteosarcoma patient. J Oncol Pharm Pract. 2021 Jun;27(4):1000-1004. doi: 10.1177/1078155220953878. Epub 2020 Sep 2. PMID: 32878553.

Eichler M, Hentschel L, Richter S, Hohenberger P, Kasper B, Andreou D, Pink D, Jakob J, Singer S, Grützmann R, Fung S, Wardelmann E, Arndt K, Heidt V, Hofbauer C, Fried M, Gaidzik VI, Verpoort K, Ahrens M, Weitz J, Schaser KD, Bornhäuser M, Schmitt J, Schuler MK, The PROSa Study Group. The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany-Cross-Sectional Results of a Nationwide Observational Study (PROSa). Cancers (Basel). 2020 Nov 30;12(12):E3590. doi: 10.3390/cancers12123590. PMID: 33266287.

Eichler M, Singer S, Hentschel L, Richter S, Hohenberger P, Kasper B, Andreou D, Pink D, Jakob J, Grützmann R, Fung S, Wardelmann E, Arndt K, Heidt V, Bonilla SAZ, Gaidzik VI, Jambor HK, Weitz J, Schaser KD, Bornhäuser M, Schmitt J, Schuler MK. The association of Health-Related Quality of Life and 1-year-survival in sarcoma patients-results of a Nationwide Observational Study (PROSa). Br J Cancer. 2022 May;126(9):1346-1354. doi: 10.1038/s41416-022-01702-z. Epub 2022 Jan 20. PMID: 35058591; PMCID: PMC9042816.

Heilig CE, Laßmann A, Mughal SS, Mock A, Pirmann S, Teleanu V, Renner M, Andresen C, Köhler BC, Aybey B, Bauer S, Siveke JT, Hamacher R, Folprecht G, Richter S, Schröck E, Brandts CH, Ahrens M, Hohenberger P, Egerer G, Kindler T, Boerries M, Illert AL, von Bubnoff N, Apostolidis L, Jost PJ, Westphalen CB, Weichert W, Keilholz U, Klauschen F, Beck K, Winter U, Richter D, Möhrmann L, Bitzer M, Schulze-Osthoff K, Brors B, Mechtersheimer G, Kreutzfeldt S, Heining C, Lipka DB, Stenzinger A, Schlenk RF, Horak P, Glimm H, Hübschmann D, Fröhling S.,Gene expression-based prediction of pazopanib efficacy in sarcoma.
Eur J Cancer. 2022 Sep;172:107-118. doi: 10.1016/j.ejca.2022.05.025. Epub 2022 Jun 25.
 
Berthold R, Isfort I, Erkut C, Heinst L, Grünewald I, Wardelmann E, Kindler T, Åman P, Grünewald TGP, Cidre-Aranaz F, Trautmann M, Fröhling S, Scholl C, Hartmann W.Fusion protein-driven IGF-IR/PI3K/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcoma.
Oncogenesis. 2022 Apr 22;11(1):20. doi: 10.1038/s41389-022-00394-7.
 
Wingerter A, El Malki K, Sandhoff R, Seidmann L, Wagner DC, Lehmann N, Vewinger N, Frauenknecht KBM, Sommer CJ, Traub F, Kindler T, Russo A, Otto H, Lollert A, Staatz G, Roth L, Paret C, Faber J.,
Exploiting Gangliosides for the Therapy of Ewing's Sarcoma and H3K27M-Mutant Diffuse Midline Glioma.
Cancers (Basel). 2021 Jan 29;13(3):520. doi: 10.3390/cancers13030520.

Beck O, Paret C, Russo A, Burhenne J, Fresnais M, Steimel K, Seidmann L, Wagner DC, Vewinger N, Lehmann N, Sprang M, Backes N, Roth L, Neu MA, Wingerter A, Henninger N, Malki KE, Otto H, Alt F, Desuki A, Kindler T, Faber J.Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma.
 
Trautmann M, Cheng YY, Jensen P, Azoitei N, Brunner I, Hüllein J, Slabicki M, Isfort I, Cyra M, Berthold R, Wardelmann E, Huss S, Altvater B, Rossig C, Hafner S, Simmet T, Ståhlberg A, Åman P, Zenz T, Lange U, Kindler T, Scholl C, Hartmann W, Fröhling S. Requirement for YAP1 signaling in myxoid liposarcoma.
EMBO Mol Med. 2019 May;11(5):e9889. doi: 10.15252/emmm.201809889.